UAE at a glance
- Population
- 11.5 million 2025
- Life expectancy at birth
- 83.1 years, 2024
- People aged 65 and over
- 1.8 % of people, 2025
- Health spending per person
- 2,402 US$ per person, 2023
- Doctors
- 2.99 per 1,000 people, 2023
Updated
Reviewed by Vidhi Upadhyay
UAE Lp(a) Targeted Therapies Market Industry Trends and Forecast to 2034: Segmented by (Drug Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$55.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $0.5 Mn | — | — |
| 2025 (base) | $0.8 Mn | +$0.3 Mn | — |
| 2026 (forecast) | $1.3 Mn | +$0.5 Mn | +61% |
| 2027 (forecast) | $2.0 Mn | +$0.8 Mn | +159.2% |
| 2028 (forecast) | $3.2 Mn | +$1.2 Mn | +317.3% |
| 2029 (forecast) | $5.2 Mn | +$2.0 Mn | +571.9% |
| 2030 (forecast) | $8.4 Mn | +$3.2 Mn | +981.8% |
| 2031 (forecast) | $13.5 Mn | +$5.1 Mn | +1,641.6% |
| 2032 (forecast) | $21.8 Mn | +$8.3 Mn | +2,704% |
| 2033 (forecast) | $35.1 Mn | +$13.3 Mn | +4,414.5% |
| 2034 (forecast) | $56.5 Mn | +$21.4 Mn | +7,168.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $0.8 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $56.5 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 61.0% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug type, indication and end user (see all) |
| Key players | Novartis AG, Amgen Inc., Eli Lilly and Company, Silence Therapeutics, Ionis Pharmaceuticals (see all) |
| Regulator in the UAE | EDESource: Emirates Drug Establishment. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Lp(a) targeted therapies lower lipoprotein(a), an inherited risk factor for heart disease that current cholesterol drugs do not treat well.
Key segments of the lp(a) Targeted Therapies market include drug type (Antisense Oligonucleotides, siRNA and Oral Small Molecules) and indication (Cardiovascular Event Prevention and Aortic Valve Stenosis).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the lp(a) Targeted Therapies market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the lp(a) Targeted Therapies market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the lp(a) Targeted Therapies market. Long-term safety data and lifestyle support are still needed for many patients.
The lp(a) Targeted Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The Emirates Drug Establishment (EDE), set up in 2023, is taking over the regulation of medicines from the Ministry of Health and Prevention.[1] Since January 2025, basic health insurance has been mandatory for all private-sector employees and domestic workers in every emirate.[2]
[1] Emirates Drug Establishment. Checked 14 Nov 2026.
[2] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for lp(a) Targeted Therapies. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UAE.
What doctors and scientists are doing in Lp(a) Targeted Therapies right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
UAE · 2 shared keywords
UAE · 1 shared keyword
UAE
UAE
UAE
UAE
Digital Health · UAE
Medical Devices · UAE
Medical Devices · UAE
Medical Devices · UAE
Medical Devices · UAE
Medical Devices · UAE